Avacta Group
AVCT · AIM · Health Care · mcap £287m · 65.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Capital Access Window - Avacta Group Plc | −5.6% | |
| 06 Oct 26 | Results | Results of Placing and Subscription
Avacta raised £12.5m through placing and subscription at 68p per share. |
−5.6% |
| 05 Oct 26 | Fundraise | Proposed Fundraise to raise approximately £12.5m
Avacta to raise £12.5m via placing and subscription at 68p per share to extend cash runway. |
+0.0% |
| 30 Sep 26 | Capital Access Window - Avacta Group Plc | +0.0% | |
| 30 Sep 26 | Capital Access Window
Avacta announces equity fundraise and enters Capital Access Window to strengthen cash runway through 2027. |
+0.0% | |
| 30 Sep 26 | Results | Half-year Results
H1 2026 interim results show clinical validation of pre|CISION platform with AVA6103 Phase 1 data and £19m raised. |
+0.0% |
| 25 Sep 26 | Pre|CISION® Platform Wins R&D Achievement Award
Avacta's pre|CISION® Platform wins Research and Development Achievement Award from Pharma Industry Awards UK 2026. |
−1.6% | |
| 25 Sep 26 | Further Demonstration of Potential of AVA6103
Avacta presents FOCUS-01 trial design and preclinical data for AVA6103 in pancreatic cancer at AACR conference. |
−1.6% | |
| 16 Sep 26 | Clinical Proof of Mechanism for preCISION Platform
AVA6103 achieves clinical proof of mechanism in Phase 1 trial with favorable safety and controlled-release pharmacokinetics. |
−1.8% | |
| 14 Sep 26 | Board change | Mats Blom to Board as Chair of Audit Committee
Mats Blom appointed to Board as Chair of Audit Committee; Paul Fry stepping down effective 30 September 2026. |
+3.4% |
| 04 Sep 26 | Accelerated Payment Convertible Bond Installment
Avacta settles accelerated convertible bond payment of £2.613m in cash, reducing principal to £12.0m. |
+2.3% | |
| 01 Sep 26 | Share Option Awards to Management Team at Avacta
Board grants share options to management team including 13.4m options to CEO at 69p exercise price. |
−0.3% | |
| 09 Jul 26 | Accelerated Amortized Payment of Bond Installment
Avacta settled accelerated convertible bond payment of £3.67m in cash; remaining principal £16.8m. |
+1.4% | |
| 08 Jul 26 | Board change | Avacta Appoints Patrick Vink Deputy Chairman
Avacta appoints Patrick Vink, pharmaceutical executive, as Non-Executive Deputy Chairman and Senior Independent Director. |
−1.4% |
| 25 Jun 26 | Platform-Validating Data with Faridoxorubicin
Faridoxorubicin shows tumor responses in salivary gland cancer patients with low FAP expression, validating platform. |
+4.8% | |
| 25 Jun 26 | FDA Agreement on Pivotal Trial Design for AVA6000
FDA agrees pivotal trial design for AVA6000 in salivary gland cancer with progression-free survival as primary endpoint. |
+4.8% | |
| 22 Jun 26 | Year-to-date business update ahead of AGM
AVA6103 Gen Two now dosing patients; raised £41.5m in 18 months; extended runway to early Q1 2027. |
−1.4% | |
| 05 Jun 26 | Fundraise | Oversubscribed Strategic Equity Fundraise of £9m
Avacta raised £9m at 70p per share to repay convertible bond debt and fund clinical milestones. |
+2.1% |
| 01 Jun 26 | Clinical data on AVA6000 in salivary gland cancers
AVA6000 shows multiple confirmed responses in salivary gland cancer patients with favorable safety profile and removal of lifetime doxorubicin limit. |
−6.3% | |
| 29 May 26 | Board Director Changes
Richard Hughes becomes non-executive Chairman following AGM on June 22; Shaun Chilton steps down after four years. |
+4.6% | |
| 19 May 26 | Results | Unaudited Preliminary Full Year 2025 Results
Clinical-stage biotech reports first patient enrolled in AVA6103 Phase 1 trial; raised £32.5m over 18 months. |
−3.0% |
| 13 May 26 | Notice of Preliminary Results and Presentation
Notice of preliminary results for FY25 to be announced May 19, 2026 with CEO and CFO investor presentation. |
+4.1% | |
| 06 May 26 | Pre|CISION® payload release vs approved ADCs
Avacta presents data showing pre|CISION® payload delivery advantages over approved ADCs and dual payload efficacy. |
−7.8% | |
| 21 Apr 26 | Avacta data AACR underline AVA6103 profile
Avacta presents preclinical and clinical data on AVA6103 and dual payload technology at AACR conference. |
+3.4% | |
| 14 Apr 26 | Christina Coughlin - In Vivo 2026 Rising Leader
CEO Christina Coughlin named as one of In Vivo's 2026 Rising Leaders in biopharma industry. |
+5.9% | |
| 09 Apr 26 | Q1 2026 Business Update
First patient treated in AVA6103 trial; Gen One program lifted dose limits; £10m financing completed. |
+4.1% | |
| 08 Apr 26 | Science Day 2026
Avacta announces Science Day event on May 6, 2026 in London to present scientific achievements. |
+3.0% | |
| 31 Mar 26 | First patient treated in Phase 1 trial of AVA6103
First patient dosed in Phase 1 trial of AVA6103, a sustained-release exatecan drug conjugate for advanced cancers. |
−1.6% | |
| 27 Mar 26 | Fundraise | Result of Oversubscribed Fundraise
Company raises £10m gross proceeds through placing and subscription at 63p per share. |
−4.8% |
| 26 Mar 26 | Fundraise | Proposed Fundraise to raise approximately £10m
Proposed placing and subscription to raise approximately £10 million at 63 pence per share. |
−1.4% |
| 17 Mar 26 | Presentations of pre|CISION® Platform Candidates
Avacta to present preclinical data on two pre|CISION platform candidates at AACR conference in April. |
−5.5% | |
| 16 Mar 26 | Phase 1 study opening for AVA6103
Phase 1 trial of FAP-Exd (AVA6103), second pipeline asset, opens for patient recruitment at US oncology centers. |
+2.8% | |
| 24 Feb 26 | PreCISION payload delivery advantage over ADC
Avacta's pre|CISION delivery platform shows favorable pharmacokinetic profile versus marketed ADC Enhertu in preclinical analysis. |
+10.6% | |
| 18 Feb 26 | Avacta to Participate in Conference March 2026
Avacta to present at TD Cowen Health Care Conference on 3 March 2026 in Boston. |
−3.6% | |
| 09 Feb 26 | Appointment of CSO
Francis Wilson appointed Chief Scientific Officer; former CSO Michelle Morrow leaving. |
+1.7% | |
| 03 Feb 26 | Faridoxorubicin Program Clinical Updates
Faridoxorubicin trial protocol updated: cardiac dosing limit removed, path to dose selection identified. |
+14.1% | |
| 21 Jan 26 | FDA Clearance of IND Application for AVA6103
FDA clears IND application for AVA6103, second pre|CISION® program; Phase 1 trial to begin Q1 2026. |
+4.7% | |
| 20 Jan 26 | Trading update | Year-end trading update
Avacta reports progress on two clinical programs, raised £22.5m equity, and has cash runway to Q3 2026. |
−4.5% |
| 20 Jan 26 | Appointment of Nominated Adviser & TVR
The Company's issued ordinary share capital is 440,415,495 Ordinary Shares. |
−4.5% | |
| 18 Dec 25 | Avacta reports new AVA6103 pharmacology data
Avacta reports preclinical pharmacology data for FAP-Exd showing sustained tumor release over five days ahead of Phase 1 in Q1 2026. |
−9.7% | |
| 17 Dec 25 | Faridoxorubicin Phase 1b SGC data
Phase 1b trial of faridoxorubicin shows confirmed partial and minor responses in salivary gland cancer patients with 90% disease control rate. |
−8.9% | |
| 08 Dec 25 | Preliminary Data in Faridoxorubicin Phase 1b Trial
Avacta to announce preliminary Phase 1b data for faridoxorubicin in salivary gland cancer on 17 December 2025. |
−0.3% | |
| 03 Nov 25 | Fundraise | Completion of Placing and TVR
Placing of 25.4m shares completed; convertible bond amendments take effect. |
+2.9% |
| 27 Oct 25 | Avacta presents preclinical data at AACR-NCI-EORTC
Avacta presents preclinical data for dual payload pre|CISION® medicines showing synergistic anti-tumor activity at AACR-NCI-EORTC conference. |
+4.2% | |
| 23 Oct 25 | Notice of Investor Presentation
Christina Coughlin, Chief Executive Officer, David Liebowitz, Chief Medical Officer, Francis Wilson, VP Chemistry and Ruairidh Edwards, Translational Scientist will deliver a presentation via Investor Meet Company at 16: |
−0.8% | |
| 20 Oct 25 | Fundraise | Equity fundraise of £16 million
Avacta raised £16 million through placing of 25.4 million shares at 63 pence each. |
−5.8% |
| 20 Oct 25 | Avacta Presents Phase 1a Data for Faridoxorubicin
Phase 1a data for faridoxorubicin shows median PFS not reached in salivary gland cancer with disease control rate of 91% and no severe cardiac toxicity. |
−5.8% | |
| 13 Oct 25 | Avacta to present data at EORTC-NCI-AACR
Avacta to present data on first dual payload peptide drug conjugate platform at EORTC-NCI-AACR conference. |
+1.4% |
Company filings. Not investment advice.